Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology, has announced it has agreed to sell approximately 16.6 million shares of its common stock to a select group of institutional and accredited investors in a private placement, at a price per share of US$7.21. Gross proceeds are expected to be approximately US$120 million, before deducting offering expenses. The financing is expected to close on July 15, 2022, subject to customary closing conditions. Latham & Watkins LLP represents Gossamer Bio in the financing with a San Diego team led by partners Matt Bush and Kevin Reyes, with associates Shelby Harrison and Alex Stuart-Lovell.~~